Blockchain Registration Transaction Record

VERAXA Biotech Advances Bispecific Antibody Pipeline with BiTAC Platform

VERAXA Biotech advances its BiTAC platform for bispecific ADCs and T-cell engagers, with lead TCE entering development and VXA-222 progressing beyond discovery.

This news matters because VERAXA’s AND-gated BiTAC platform could meaningfully reduce the off-tumor toxicity that has long limited the therapeutic window of antibody-based cancer treatments. By requiring two tumor-associated targets for activation, the approach may enable more precise tumor killing while sparing healthy tissue—a potential game-changer for patients with hard-to-treat cancers. The progress of the lead BiTAC-TCE into cell-line development and planned IND/CTA-enabling work, along with VXA-222’s advancement beyond antibody discovery, signals that the company is moving from concept toward clinical reality. For investors, these milestones could represent near-term catalysts and validate VERAXA’s technology platform, which is built on foundational research from the European Molecular Biology Laboratory. As the oncology landscape increasingly shifts toward smarter, more targeted immunotherapies, VERAXA’s dual-targeting strategy positions it among the innovators aiming to solve one of the field’s most persistent challenges.